22nd Apr 2025 11:32
(Alliance News) - AOTI Inc on Tuesday announced that its multi-modality topical wound oxygen therapy will be included in the latest NHS supply chain framework agreement.
The Oceanside, California-based medical technology company said the TWO2 therapy has been awarded inclusion by NHS Supply Chain to the framework agreement for Advanced Wound Care 2025, which becomes effective on September 1. NHS supply chain framework agreements can run for up to 48 months, and "provide a single route to market for suppliers".
AOTI's TWO2 products consist of the TWO2 Extremity Chamber, which helps treat acute or chronic leg wounds and diabetic foot ulcers, and the TWO2 multi-patch system for use on wounds and ulcers.
AOTI said this follows the publication of new study results demonstrating that the adoption of TWO2 within the NHS in England "would significantly lower overall diabetic foot care costs", by an estimated GBP5,038 or 16% per patient over two years compared to the stand cost of GBP31,275.
The "comprehensive health economic model" developed by the study's authors, AOTI said, also predicted that TWO2 would increase patients' quality adjusted life years and "significantly improve outcomes relative to standard care".
AOTI noted that the estimated cost of diabetic foot disease in England is currently "almost 1% of the entire annual NHS budget, which is forecast to reach GBP192 billion in 2025, with non-healing ulcers being the major cost driver".
"It is exciting to see acknowledgement of the clinical and health economic benefits delivered by our unique cyclical-pressure TWO2 therapy with its inclusion in the new framework agreement for Advanced Wound Care," commented Chief Executive Officer Mike Griffiths. "Once implemented patients across England will have easier access to our proven limb saving outcomes and the NHS can start to realise substantial cost savings.
"These benefits are driven by significantly reduced wound recurrence, hospitalisations and amputations, all of which translate to improved quality of life for patients living with these non-healing foot ulcers."
Shares in AOTI were untraded at 82.50 pence in London on Tuesday, giving it a market capitalisation of GBP87.8 million.
By Emma Curzon, Alliance News reporter
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
Aoti, Inc.